• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    19.01 -0.45 (-2.31%)
    Streaming Delayed Price Updated: 10:15 AM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sarepta Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
    Via Investor Brand Network
    NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Sarepta Therapeutics to Participate in Upcoming Investor Conferences
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    Via Investor Brand Network
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.